UK Parliament home

This petition was submitted during the 2010 to 2015 Parliament

View other petitions from this Parliament

Closed Health Ministers to approve funding  for a National Specialised Service  and the use of Eculizumab for aHUS patients without delay

Closed on

We welcome the  advice from the independent body AGNSS that people with aHUS in England should be treated with Eculizumab if they need it. 

We deplore the Health Minister's decision to delay  implementation of the recommendation by asking NICE to complete a duplicate assessment, thus  prolonging the wait for patients whose lives could be saved or transformed by this drug. 

10,662 signatures

Show on a map

100,000

Petition progress

View all updates for this petition, with the most recent first.

  • Petition closed

  • Government responded to this petition

    As this e-petition has received more than 10 000 signatures, the relevant Government department have provided the following response:

    The Advisory Group for National Specialised Services (AGNSS) considered the application for eculizumab (Soliris) for the treatment of atypical haemolytic uremic syndrome (aHUS) to be included as part of national commissioning arrangements. Whilst AGNSS members were convinced of the clinical effectiveness of the drug, they noted its very high cost and the increasing cost profile for the NHS, which is predicted to rise significantly.

    In considering the recommendation from the AGNSS, the Department took advice on AGNSS’s assessment of the cost impact and affordability of eculizumab. The Department of Health accepted AGNSS’s advice concerning the clinical effectiveness of the drug, but felt further advice was needed on its suitability for direct commissioning taking account of its costs, benefits and affordability. As the AGNSS no longer exists as a Ministerial advisory group, the Department of Health has asked the National Institute for Health and Care Excellence (NICE) to undertake this further work as part of its new highly specialised technologies programme. NICE assumed responsibility for this work on 1 April.

    NHS England is developing an interim policy to enable patients to receive eculizumab while NICE undertakes its evaluation. This will mean that patients who were previously receiving eculizumab through arrangements with their primary care trust will continue to receive the drug and any newly diagnosed patients will also be funded. NHS England has assured the Department that patients who are critically ill and who need eculizumab urgently will receive it.

    This e-petition remains open to signatures and will be considered for debate by the Backbench Business Committee should it pass the 100 000 signature threshold.

  • Government will respond to this petition

    This petition got more than 10,000 signatures meaning that government will respond to it.

  • Petition published

    This petition can now be signed.

    If this petition gets 10,000 signatures, government will respond to it.

    If this petition gets 100,000 signatures, it will be considered for debate in Parliament.

    This petition will stay open until 25 August 2013.